Trans-Cinnamaldehyde inhibition of cytoskeleton-induced invasion and migration by regulating the Rho/ROCK pathway in adenomyosis
preprint
OA: gold
CC0
Abstract
Some of the key steps in adenomyosis (AM) are the migration and invasion of adenomyosis derived cells (AMDC); these processes require rearrangement of the cytoskeleton which Rho/ROCK signaling pathway is involved. The aim of the current study was to verify AMDC characterization and the effect of Trans-Cinnamaldehyde (TC) on the expression of the cell viability and cytotoxicity, cytoskeleton, invasion, migration, RhoA, RhoB, RhoC, ROCK1, ROCK2 in AMDC, which by immunofluorescence, CCK-8, immunofluorescence, cell wound scratch assay, transwell invasion assay and western blot analysis. Human endometrium tissues were obtained from AM patients who underwent total hysterectomy for AM in the Linyi Central Hospital from September 2019 to May 2021 with the first patient 41 years old and second one 45 years old. AMDC was characterized with strongly positive staining for Vimentin and almost negative for CK7, VWF, E-cadherin, SMA, and the patient samples were in secretory phases. IC50 = 28.93±0.44 μg/mL at 48 h with first patient, and IC50 = 27.67±0.72 μg/mL with second one. The final concentrations of TC (0, 6, 12μg/mL) were selected of the cell cytotoxicity. The T-text test group >0.05, so there was no difference between the two patients. These experiments were significantly downregulated and in dose-dependent fashion after treatment with TC. The data suggest that TC can inhibition the viability of cell, regulate cytoskeleton-induced invasion and migration may related to Rho/ROCK signaling pathway are involved in the pathophysiology of adenomyosis. Keyword: Cytoskeleton, Invasion, Migration, Rho/ROCK pathway, Trans-Cinnamaldehyde, Adenomyosis
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (37)
- Adenomyosis and junctional zone changes in patients with endometriosis via openalex
- A prospective cohort study of endometriosis and subsequent risk of infertility via openalex
- Clonogenicity of Human Endometrial Epithelial and Stromal Cells1 via openalex
- Endometriosis and cancer: a systematic review and meta-analysis via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex
- Single-cell transcriptomic analysis of eutopic endometrium and ectopic lesions of adenomyosis via openalex
- Single-cell Transcriptomic Analysis of Eutopic Endometrium and Ectopic Lesions of Adenomyosis via openalex
- The elusive adenomyosis of the uterus—revisited via openalex
- Traditional Chinese medicine prescription Guizhi Fuling Pills in the treatment of endometriosis via openalex
- W2526786375 via openalex
- W2607357221 via openalex
- W2754839611 via openalex
- W2774885482 via openalex
- W2795549746 via openalex
- W2905271078 via openalex
- W2968698332 via openalex
- W3012614716 via openalex
- W3016032408 via openalex
- W3027906585 via openalex
- W3036214521 via openalex
- W3048017709 via openalex
- W3085854774 via openalex
- W3208885340 via openalex
- W3212527301 via openalex
- W6646706362 via openalex
- W1078723032 via openalex
- W6685254831 via openalex
- W1685280444 via openalex
- W1984086927 via openalex
- W1984880853 via openalex
- W1999843687 via openalex
- W2012412328 via openalex
- W2100473445 via openalex
- W2171501785 via openalex
- W2407550888 via openalex
- W2460622308 via openalex
Source provenance
- europepmc
- last seen: 2026-06-04T01:45:00.660873+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK